A large single-center experience with allogeneic stem-cell transplantation for peripheral XXXX and @entity4888 .

@entity1 @entity4888 @entity784 @entity3191 @entity2132 @entity2108
BACKGROUND: The prognosis for @entity1 with most forms of @entity784 is poor. Allogeneic hematopoietic stem-cell transplantation (HSCT) may improve the outcome. @entity1 AND METHODS: This study examines the outcome of 52 @entity1 who underwent ablative or nonablative allogeneic HSCT for @entity3191 ( @entity3191 ) or @entity4888 over a 12-year period at a single institution. We divided the @entity1 into those with predominantly nodal histologies: peripheral T-cell not otherwise specified ( @entity3191 NOS), angioimmunoblastic (AITL), or @entity2108 , T/null type (systemic) (ALCL), and predominantly extranodal histologies: natural killer (NK)/T cell, enteropathy type, hepatosplenic, subcutaneous @entity4888 , or T cell or NK cell other. RESULTS: Median follow-up of survivors is 49 months. Non-relapse mortality and relapse at 3 years was 27% and 43%, respectively. The incidence of @entity2132 ( @entity2132 ) was 21%. The incidence of extensive chronic @entity2132 at 2 years was 27%. The 3-year progression-free survival was 30%: 45% in @entity1 with predominantly nodal histologies ( @entity3191 NOS, AITL, and ALCL) and 6% in @entity1 with predominantly extranodal histologies (P   =   0.016). Overall survival at 3 years was 41% for all @entity1 . CONCLUSION: Allogeneic HSCT can produce long-term remissions in relapsed/ @entity784 , especially those with nodal histologies.
